Sahana Nagabhushan Kalburgi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Sahana Nagabhushan Kalburgi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Steven James Gray
Gene Therapy Center, University of North Carolina at Chapel Hill, 7119 Thurston Bowles, Campus Box 7352, Chapel Hill, NC, 27599-7352, USA. graysj@.unc.edu
5 shared publications Lavanya Bachaboina
University of North Carolina at Chapel Hill
2 shared publicationsRachel M. Bailey
Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2 shared publicationsAnne E West
Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
1 shared publication- Bart Devreese
Laboratory of Microbiology (Protein Research Unit), Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
1 shared publication Boris Kantor
Department of Pharmacology, Physiology, and Neuroscience, University of South Carolina, Columbia, SC, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2018
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 9, 160-171
Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy
- 1 June 2018
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 9, 160-171
Open AccessDevelopment of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy
- 19 May 2016
- Published by SAGE Publications in Human Gene Therapy
- Vol. 27 (7) , 509-521
Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease
G M2 gangliosidosis is a family of three genetic neurodegenerative disorders caused by the accumulation of G M2 ganglioside (G M2 ) in neuronal tissue. Two of these are due to the deficiency of the heterodimeric (α–β), “A” isoenzyme of lysosomal β-hexosaminidase (HexA). Mutations in the α-subunit (encoded by HEXA ) lead to Tay-Sachs disease (TSD), whereas mutations in the β-subunit (encoded by HEXB ) lead to Sandhoff disease (SD). The third form results from a deficiency of the G M2 activator protein (G M2 AP), a substrate-specific cofactor for HexA. In their infantile, acute forms, these diseases rapidly progress with mental and psychomotor deterioration resulting in death by approximately 4 years of age. After gene transfer that overexpresses one of the deficient subunits, the amount of HexA heterodimer formed would empirically be limited by the availability of the other endogenous Hex subunit. The present study used a new variant of the human HexA α-subunit, μ, incorporating critical sequences from the β-subunit that produce a stable homodimer (HexM) and promote functional interactions with the G M2 AP– G M2 complex. We report the design of a compact adeno-associated viral (AAV) genome using a synthetic promoter–intron combination to allow self-complementary (sc) packaging of the HEXM gene. Also, a previously published capsid mutant, AAV9.47, was used to deliver the gene to brain and spinal cord while having restricted biodistribution to the liver. The novel capsid and cassette design combination was characterized in vivo in TSD mice for its ability to efficiently transduce cells in the central nervous system when delivered intravenously in both adult and neonatal mice. This study demonstrates that the modified HexM is capable of degrading long-standing G M2 storage in mice, and it further demonstrates the potential of this novel scAAV vector design to facilitate widespread distribution of the HEXM gene or potentially other similar-sized genes to the nervous system.
- 19 May 2016
- Published by SAGE Publications in Human Gene Therapy
- Vol. 27 (7) , 509-521
Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease
G M2 gangliosidosis is a family of three genetic neurodegenerative disorders caused by the accumulation of G M2 ganglioside (G M2 ) in neuronal tissue. Two of these are due to the deficiency of the heterodimeric (α–β), “A” isoenzyme of lysosomal β-hexosaminidase (HexA). Mutations in the α-subunit (encoded by HEXA ) lead to Tay-Sachs disease (TSD), whereas mutations in the β-subunit (encoded by HEXB ) lead to Sandhoff disease (SD). The third form results from a deficiency of the G M2 activator protein (G M2 AP), a substrate-specific cofactor for HexA. In their infantile, acute forms, these diseases rapidly progress with mental and psychomotor deterioration resulting in death by approximately 4 years of age. After gene transfer that overexpresses one of the deficient subunits, the amount of HexA heterodimer formed would empirically be limited by the availability of the other endogenous Hex subunit. The present study used a new variant of the human HexA α-subunit, μ, incorporating critical sequences from the β-subunit that produce a stable homodimer (HexM) and promote functional interactions with the G M2 AP– G M2 complex. We report the design of a compact adeno-associated viral (AAV) genome using a synthetic promoter–intron combination to allow self-complementary (sc) packaging of the HEXM gene. Also, a previously published capsid mutant, AAV9.47, was used to deliver the gene to brain and spinal cord while having restricted biodistribution to the liver. The novel capsid and cassette design combination was characterized in vivo in TSD mice for its ability to efficiently transduce cells in the central nervous system when delivered intravenously in both adult and neonatal mice. This study demonstrates that the modified HexM is capable of degrading long-standing G M2 storage in mice, and it further demonstrates the potential of this novel scAAV vector design to facilitate widespread distribution of the HEXM gene or potentially other similar-sized genes to the nervous system.
- 1 January 2014
- Published by Elsevier
- Vol. 87, 125-197
Methods for Gene Transfer to the Central Nervous System
- 1 January 2014
- Published by Elsevier
- Vol. 87, 125-197
Methods for Gene Transfer to the Central Nervous System
- 1 February 2013
- Vol. 15 (81) , 111-9
Recent gene therapy advancements for neurological diseases.
The past few years have seen rapid advancements in vector-mediated gene transfer to the nervous system and modest successes in human gene therapy trials. The purpose of this review is to describe commonly-used viral gene transfer vectors and recent advancements towards producing meaningful gene-based treatments for central nervous system (CNS) disorders. Gene therapy trials for Canavan disease, Batten disease, adrenoleukodystrophy, and Parkinson's disease are discussed to illustrate the current state of clinical gene transfer to the CNS. Preclinical studies are under way for a number of diseases, primarily lysosomal storage disorders, using a newer generation of vectors and delivery strategies. Relevant studies in animal models are highlighted for Mucopolysaccharidosis IIIB and Krabbe disease to provide a prelude for what can be expected in the coming years for human gene transfer trials, using recent advancements in gene transfer technology. In conclusion, recent improvements in CNS gene transfer technology are expected to significantly increase the degree of disease rescue in future CNS-directed clinical trials, exceeding the modest clinical successes that have been observed so far.
- 1 February 2013
- Vol. 15 (81) , 111-9
Recent gene therapy advancements for neurological diseases.
The past few years have seen rapid advancements in vector-mediated gene transfer to the nervous system and modest successes in human gene therapy trials. The purpose of this review is to describe commonly-used viral gene transfer vectors and recent advancements towards producing meaningful gene-based treatments for central nervous system (CNS) disorders. Gene therapy trials for Canavan disease, Batten disease, adrenoleukodystrophy, and Parkinson's disease are discussed to illustrate the current state of clinical gene transfer to the CNS. Preclinical studies are under way for a number of diseases, primarily lysosomal storage disorders, using a newer generation of vectors and delivery strategies. Relevant studies in animal models are highlighted for Mucopolysaccharidosis IIIB and Krabbe disease to provide a prelude for what can be expected in the coming years for human gene transfer trials, using recent advancements in gene transfer technology. In conclusion, recent improvements in CNS gene transfer technology are expected to significantly increase the degree of disease rescue in future CNS-directed clinical trials, exceeding the modest clinical successes that have been observed so far.
- 14 January 2013
- Published by SAGE Publications in Human Gene Therapy
- Vol. 24 (2) , 209-219
Restoration of Cytoskeleton Homeostasis After Gigaxonin Gene Transfer for Giant Axonal Neuropathy
Giant axonal neuropathy (GAN) is caused by loss of function of the gigaxonin protein. On a cellular level GAN is characterized by intermediate filament (IF) aggregation, leading to a progressive and fatal peripheral neuropathy in humans. This study sought to determine if re-introduction of the GAN gene into GAN -deficient cells and mice would restore proper cytoskeleton IF homeostasis. Treatment of primary skin fibroblast cultures from three different GAN patients with an adeno-associated virus type 2 (AAV2) vector containing a normal human GAN transgene significantly reduced the number of cells displaying vimentin IF aggregates. A proteomic analysis of these treated cells was also performed, wherein the abundance of 32 of 780 identified proteins significantly changed in response to gigaxonin gene transfer. While 29 of these responding proteins have not been directly described in association with gigaxonin, three were previously identified as being disregulated in GAN and were now shifted toward normal levels. To assess the potential application of this approach in vivo and eventually in humans, GAN mice received an intracisternal injection of an AAV9/GAN vector to globally deliver the GAN gene to the brainstem and spinal cord. The treated mice showed a nearly complete clearance of peripherin IF accumulations at 3 weeks post-injection. These studies demonstrate that gigaxonin gene transfer can reverse the cellular IF aggregate pathology associated with GAN.
- 14 January 2013
- Published by SAGE Publications in Human Gene Therapy
- Vol. 24 (2) , 209-219
Restoration of Cytoskeleton Homeostasis After Gigaxonin Gene Transfer for Giant Axonal Neuropathy
Giant axonal neuropathy (GAN) is caused by loss of function of the gigaxonin protein. On a cellular level GAN is characterized by intermediate filament (IF) aggregation, leading to a progressive and fatal peripheral neuropathy in humans. This study sought to determine if re-introduction of the GAN gene into GAN -deficient cells and mice would restore proper cytoskeleton IF homeostasis. Treatment of primary skin fibroblast cultures from three different GAN patients with an adeno-associated virus type 2 (AAV2) vector containing a normal human GAN transgene significantly reduced the number of cells displaying vimentin IF aggregates. A proteomic analysis of these treated cells was also performed, wherein the abundance of 32 of 780 identified proteins significantly changed in response to gigaxonin gene transfer. While 29 of these responding proteins have not been directly described in association with gigaxonin, three were previously identified as being disregulated in GAN and were now shifted toward normal levels. To assess the potential application of this approach in vivo and eventually in humans, GAN mice received an intracisternal injection of an AAV9/GAN vector to globally deliver the GAN gene to the brainstem and spinal cord. The treated mice showed a nearly complete clearance of peripherin IF accumulations at 3 weeks post-injection. These studies demonstrate that gigaxonin gene transfer can reverse the cellular IF aggregate pathology associated with GAN.
- Open Access
- 1 January 2013
- Published by Elsevier in Molecular Therapy
- Vol. 21 (1) , 18-30
Improved Survival and Reduced Phenotypic Severity Following AAV9/MECP2 Gene Transfer to Neonatal and Juvenile Male Mecp2 Knockout Mice
- 1 January 2013
- Published by Elsevier in Molecular Therapy
- Vol. 21 (1) , 18-30
Open AccessImproved Survival and Reduced Phenotypic Severity Following AAV9/MECP2 Gene Transfer to Neonatal and Juvenile Male Mecp2 Knockout Mice
- 1 August 2012
- Published by Elsevier in Behavioural Brain Research
- Vol. 233 (2) , 536-544
Fear conditioning can contribute to behavioral changes observed in a repeated stress model
- 1 August 2012
- Published by Elsevier in Behavioural Brain Research
- Vol. 233 (2) , 536-544
Fear conditioning can contribute to behavioral changes observed in a repeated stress model